Workflow
佳兆业健康(00876) - 2020 - 中期财报
KAISA HEALTHKAISA HEALTH(HK:00876)2020-09-18 08:01

Financial Performance - Revenue for the six months ended June 30, 2020, was HKD 76,175,000, a decrease of 36% compared to HKD 118,818,000 for the same period in 2019[13] - Gross profit for the period was HKD 36,916,000, down from HKD 58,693,000 in the previous year, reflecting a decline in gross margin[13] - The company reported a loss of HKD 6,329,000 for the six months ended June 30, 2020, compared to a profit of HKD 5,311,000 in the same period of 2019[13] - Total comprehensive loss for the period was HKD 14,695,000, compared to a total comprehensive income of HKD 1,826,000 in the same period last year[13] - Basic and diluted loss per share was HKD (0.12) for the current period, compared to earnings of HKD 0.11 per share in the previous year[13] - The company reported a pre-tax loss of HKD 6,494,000 for the six months ended June 30, 2020, compared to a profit of HKD 5,005,000 in the same period of 2019[42] - The loss attributable to equity holders of the company was approximately HKD 6.1 million, compared to a profit of HKD 5.4 million in the same period of 2019[157] Expenses and Costs - The company experienced a significant increase in selling and distribution costs, which amounted to HKD 12,767,000, compared to HKD 22,598,000 in the previous year[13] - Administrative expenses increased to HKD 38,481,000 from HKD 34,247,000 year-on-year, indicating rising operational costs[13] - The company incurred research and development expenses of HKD 9,187,000, a decrease of 35.3% from HKD 14,292,000 in the previous year[76] - The company recognized a finance cost of HKD 283,000 related to lease liabilities, an increase from HKD 143,000 in the previous year[75] Assets and Liabilities - As of June 30, 2020, total assets amounted to HKD 1,030,473 thousand, a decrease from HKD 1,014,857 thousand as of December 31, 2019, reflecting a growth of approximately 1.5%[14] - Current liabilities rose to HKD 76,894 thousand, up from HKD 67,886 thousand, indicating an increase of approximately 13.5%[14] - The company’s total liabilities increased to HKD 391,824 thousand from HKD 373,196 thousand, reflecting a rise of approximately 5.0%[14] - The total equity attributable to equity holders of the company decreased to HKD 628,228 thousand from HKD 642,007 thousand, a reduction of about 2.1%[15] - The company’s reserves decreased to HKD 621,925 thousand from HKD 635,704 thousand, a decline of about 2.2%[15] Cash Flow - The net cash used in operating activities for the six months ended June 30, 2020, was HKD (42,636) thousand, compared to HKD (128,521) thousand for the same period in 2019, showing an improvement of about 66.8%[20] - Cash and cash equivalents decreased to HKD 181,655 thousand from HKD 230,176 thousand, a decline of approximately 21.1%[20] - The company reported a net cash outflow from investing activities of HKD (23,344) thousand, a significant decrease from HKD 100,920 thousand in the previous year[20] Market and Business Strategy - The company is focusing on improving operational efficiency and exploring new market opportunities to enhance future performance[13] - The company is focusing on expanding its operations in the dental and health sectors, with ongoing assessments of market conditions and potential strategic initiatives[68] - The company aims to enhance shareholder value by expanding its denture business and integrating high-quality medical device resources domestically and internationally[171] - The company plans to establish a comprehensive hospital with 2,000 beds in Hangzhou, enhancing its health investment portfolio and market reputation in China[175] Compliance and Governance - The financial statements for the six months ended June 30, 2020, were prepared in accordance with Hong Kong Accounting Standards and applicable disclosure requirements[21] - The company confirmed compliance with the corporate governance code during the six months ended June 30, 2020[200] Shareholder Information - The board did not recommend the payment of an interim dividend for the period[158] - The total number of issued ordinary shares remained at 5,042,139,374 as of June 30, 2020, unchanged from December 31, 2019[192] - The company has adopted a share option scheme as a long-term incentive for directors and eligible employees[194]